Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emmessar Biotech And NutritionBOM:524768 +1.93%55 PB Ratio is 1.56 as of Aug. 03, 2026, which is 31% below its 10-year median of 2.26. GuruFocus rates BOM:524768 with a GF Score™ of 55/100 and a GF Value™ of ₹18.67 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 923 Drug Manufacturers companies, Emmessar Biotech And Nutrition ranks better than 56.88% on this metric.
Emmessar Biotech And Nutrition Ltd stock PB Ratio (=1.51) is close to 5-year low of 1.49.
The historical rank and industry rank for Emmessar Biotech And Nutrition's PB Ratio or its related term are showing as below:
BOM:524768'
s PB Ratio Range Over the Past 10 Years
Min: 1.21 Med: 2.26 Max: 9.04
Current: 1.59
During the past 13 years, Emmessar Biotech And Nutrition's highest PB Ratio was 9.04. The lowest was 1.21. And the median was 2.26.
BOM:524768's PB Ratio is ranked better than 56.88% of 923
companies
in the Drug Manufacturers industry
Industry Median: 1.89
vs BOM:524768: 1.59
During the past 12 months, Emmessar Biotech And Nutrition's average Book Value Per Share Growth Rate was 5.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 6.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 20.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Emmessar Biotech And Nutrition was 56.80% per year. The lowest was -22.50% per year. And the median was 9.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Emmessar Biotech And Nutrition PB Ratio Related Terms
Emmessar Biotech And Nutrition PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Emmessar Biotech And Nutrition's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmessar Biotech And Nutrition PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emmessar Biotech And Nutrition's PB Ratio distribution charts can be found below:
* The bar in red indicates where Emmessar Biotech And Nutrition's PB Ratio falls into.
Emmessar Biotech And Nutrition PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Emmessar Biotech And Nutrition (BOM:524768) has a PB Ratio of 1.56 as of Aug. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Emmessar Biotech And Nutrition and its competitors. This is 31% below median its historical median of 2.26. Over the past decade, Emmessar Biotech And Nutrition's PB Ratio has ranged from 1.21 to 9.04. According to the industry distribution chart, Emmessar Biotech And Nutrition ranks #398 out of 923 companies in the Drug Manufacturers industry, placing it in the top 43.1%.
Is Emmessar Biotech And Nutrition's PB Ratio too high?
Emmessar Biotech And Nutrition's current PB Ratio of 1.56 is 31% below median its 10-year median of 2.26. Over the past 10 years, this metric has ranged from a low of 1.21 to a high of 9.04. The Drug Manufacturers industry median PB Ratio is 1.89. Emmessar Biotech And Nutrition's value of 1.56 is 17.5% below this industry median. Based on the distribution chart, Emmessar Biotech And Nutrition ranks #398 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Emmessar Biotech And Nutrition has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emmessar Biotech And Nutrition's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Emmessar Biotech And Nutrition ranks #398 out of 923 companies for PB Ratio. This puts Emmessar Biotech And Nutrition in the upper half of its industry. The industry median PB Ratio is 1.89. Emmessar Biotech And Nutrition's value of 1.56 is 17.5% below this benchmark. Historically, Emmessar Biotech And Nutrition's own PB Ratio has ranged from 1.21 to 9.04 over the past decade. While the company's 10-year median is 2.26 vs. the industry median of 1.89, Emmessar Biotech And Nutrition has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.89, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmessar Biotech And Nutrition's current PB Ratio of 1.56 is 17.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Emmessar Biotech And Nutrition and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmessar Biotech And Nutrition's current PB Ratio is 1.56, which is 31% below median its own 10-year median of 2.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmessar Biotech And Nutrition stock overvalued right now?
Based on GuruFocus' analysis, Emmessar Biotech And Nutrition (BOM:524768) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹18.67, compared to a current price of ₹25.34 — trading 35.7% above its estimated fair value. The current PB Ratio is 1.56, which is 31% below median its 10-year median of 2.26 and 17.5% below the Drug Manufacturers industry median of 1.89. Emmessar Biotech And Nutrition's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Emmessar Biotech And Nutrition (BOM:524768), the current PB Ratio is 1.56 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emmessar Biotech And Nutrition (BOM:524768) Overvalued in 2026?
Based on GuruFocus' analysis, Emmessar Biotech And Nutrition stock appears to be overvalued.
The current stock price of ₹25.34 is trading 35.7% above its estimated GF Value™ of ₹18.67.
GuruFocus considers Emmessar Biotech And Nutrition to be Significantly Overvalued.
Key valuation signals for BOM:524768:
PB Ratio: 1.56 (31% below median its 10-year median of 2.26)
GF Value™: ₹18.67 vs. price of ₹25.34 (35.7% above fair value)
Industry Position: 17.5% below the Drug Manufacturers median (#398 of 923)
No single metric tells the full story. See the BOM:524768 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emmessar Biotech And Nutrition Ltd is a healthcare company. The company is engaged in the manufacturing and marketing of fine chemicals products, and healthcare and nutritional products. The company caters to patients with obstinate skin problems, muscle problems, bone problems, and other debilitating chronic physical ailments. The business segments of the company are Healthcare, Fine Chemicals, and Rent on Immovable property of which the majority of the revenue is derived from the Rent on Lease land segment.
55GF Score
Get the complete analysis for BOM:524768
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524768 has been successfully added to your 
